iBio's IBIO-610 Shows Fat-Selective Weight Loss in Non-Human Primates
Event summary
- iBio reported preclinical data showing IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in obese non-human primates after two doses.
- The study demonstrated a fat-selective profile with minimal impact on lean mass, consistent with rodent studies and human trials targeting the Activin E pathway.
- IBIO-610 has an extended half-life of 33.2 days in NHPs, with a projected human half-life of up to 100 days, supporting potential twice-yearly dosing.
- Complete dataset, including additional biomarker analysis, will be presented at scientific conferences throughout 2026.
The big picture
iBio's preclinical data for IBIO-610 aligns with broader industry efforts to develop fat-selective weight loss therapies, leveraging AI-driven drug discovery platforms. The extended half-life and potential for twice-yearly dosing could position IBIO-610 as a differentiated treatment option if clinical success is achieved. The company's focus on cardiometabolic and obesity diseases reflects the growing market demand for innovative solutions in these areas.
What we're watching
- Clinical Translation
- How the fat-selective weight loss observed in NHPs will translate to human clinical trials.
- Competitive Positioning
- Whether IBIO-610 can differentiate itself from other therapies targeting the Activin E pathway.
- Regulatory Pathway
- The pace at which iBio can advance IBIO-610 through regulatory approvals for obesity and cardiometabolic indications.
Related topics